CARM1 arginine methyltransferase as a therapeutic target for cancer
Journal of Biological Chemistry · 2023-09 · 299 (9) · 105124
DOI: 10.1016/j.jbc.2023.105124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biological Chemistry, 2023-09. Verfasst von Margarida Santos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: mia…. Hauptthemen laut MEDLINE: Neoplasms, Protein-Arginine N-Methyltransferases. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Coactivator-associated arginine methyltransferase 1 (CARM1) is an arginine methyltransferase that posttranslationally modifies proteins that regulate multiple levels of RNA production and processing. Its substrates include histones, transcription factors, coregulators of transcription, and splicing factors. CARM1 is overexpressed in many different cancer types, and often promotes transcription factor programs that are co-opted as drivers of the transformed cell state, a process known as transcription factor addiction. Targeting these oncogenic transcription factor pathways is difficult but could be addressed by removing the activity of the key coactivators on which they rely. CARM1 is ubiquitously expressed, and its KO is less detrimental in embryonic development than deletion of the arginine methyltransferases protein arginine methyltransferase 1 and protein arginine methyltransferase 5, suggesting that therapeutic targeting of CARM1 may be well tolerated. Here, we will summarize the normal in vivo functions of CARM1 that have been gleaned from mouse studies, expand on the transcriptional pathways that are regulated by CARM1, and finally highlight recent studies that have identified oncogenic properties of CARM1 in different biological settings. This review is meant to kindle an interest in the development of human drug therapies targeting CARM1, as there are currently no CARM1 inhibitors available for use in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: mialmeidasantos@mdanderson.org.
- Department of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Epigenetics & Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: mtbedford@mdanderson.org.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Santos, M., Hwang, J. W., & Bedford, M. T. (2023). CARM1 arginine methyltransferase as a therapeutic target for cancer. Journal of Biological Chemistry, 299(9), 105124. https://doi.org/10.1016/j.jbc.2023.105124
Vancouver
Santos M, Hwang JW, Bedford MT. CARM1 arginine methyltransferase as a therapeutic target for cancer. Journal of Biological Chemistry. 2023;299(9):105124. doi:10.1016/j.jbc.2023.105124
BibTeX
@article{Santos2023,
author = {Santos, Margarida and Hwang, Jee Won and Bedford, Mark T},
title = {CARM1 arginine methyltransferase as a therapeutic target for cancer},
journal = {Journal of Biological Chemistry},
year = {2023},
volume = {299},
number = {9},
pages = {105124},
doi = {10.1016/j.jbc.2023.105124}
}
EUVIMED